Mantle Cell Lymphoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Acalabrutinib Yields Promising Response Rates in Relapsed ... - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Acalabrutinib Yields Promising Response Rates in Relapsed ... 
Cancer Therapy Advisor
The median time to response (TRR) was 1.9 months. The median duration of response (DoR) was not reached.
AstraZeneca's Calquence (acalabrutinib) Demonstrates Activity in ... Business Wire (press release)
AstraZeneca's CALQUENCE® (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma ... Digital Journal

all 3 news articles » 


Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up ... - Business Wire (press release)



Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up ... 
Business Wire (press release)
BEERSE, Belgium--(BUSINESS WIRE)--Today, Janssen-Cilag International NV (?Janssen?) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data ...
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3½-Year Follow-Up ... PR Newswire (press release)
IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients ... Markets Insider

all 4 news articles » 


Ibrutinib May Provide PFS Benefit in Patients With Mantle Cell Lymphoma - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Ibrutinib May Provide PFS Benefit in Patients With Mantle Cell Lymphoma 
Cancer Therapy Advisor
CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients. Our mission ...

and more » 


Predictors and Implications of Rituximab Maintenance Failure in Mantle Cell Lymphoma - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Predictors and Implications of Rituximab Maintenance Failure in Mantle Cell Lymphoma 
Cancer Therapy Advisor
Patients with mantle cell lymphoma (MCL) who fail rituximab maintenance therapy have a greatly increased risk of death, according findings being presented at the 2017 American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia.1. For this ...

and more » 


Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient ... - AJMC.com Managed Markets Network



Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient ... 
AJMC.com Managed Markets Network
Three studies presented at the ongoing 59th Annual Meeting and Exposition of the American Society of Hematology in Atlanta, Georgia, shared progress on the oral Bruton's tyrosine kinase inhibitor, ibrutinib, in the treatment of relapsed/refractory ...

and more » 


Initial and Maintenance Treatment With Rituximab/Lenalidomide ... - Targeted Oncology



Targeted Oncology
 
Initial and Maintenance Treatment With Rituximab/Lenalidomide ... 
Targeted Oncology
For patients with mantle cell lymphoma, initial and maintenance treatment with the combination of lenalidomide (Revlimid) and rituximab (Rituxan) were found to be feasible, safe, and elicit clinical activity.

and more » 


Zanubrutinib Highly Active in Non-Hodgkin Lymphoma - OncLive - OncLive



OncLive
 
Zanubrutinib Highly Active in Non-Hodgkin Lymphoma - OncLive 
OncLive
The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma (NHL), according to findings from a phase Ib study presented at the 2017 ASH Annual Meeting. Among patients with ...

and more » 


BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin's Lymphoma ... - GlobeNewswire (press release)



BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin's Lymphoma ... 
GlobeNewswire (press release)
... today presented preliminary clinical data from an ongoing Phase 1b trial of its investigational Bruton's Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111) in patients with non-Hodgkin's lymphoma (NHL) in an oral presentation at the 59th ...

and more » 


AstraZeneca and GSK start fightback after big year for blood cancer treatments - Telegraph.co.uk



Telegraph.co.uk
 
AstraZeneca and GSK start fightback after big year for blood cancer treatments 
Telegraph.co.uk
At the American Society for Haematology event yesterday, AstraZeneca unveiled detailed results for its trial of potential blockbuster drug Calquence in mantle cell lymphoma (MCL) patients. It showed the drug was effective and produced fewer side ...

 


AstraZeneca's Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials - Business Wire (press release)



AstraZeneca's Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials 
Business Wire (press release)
Acalabrutinib binds covalently to BTK, thereby inhibiting its activity, and has demonstrated this with minimal interactions with other immune cells in pre-clinical studies.3,4,5,6 In B cells, BTK signalling results in activation of pathways necessary ...